Vaxcyte, Inc. PCVX Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermInvestments.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s equity method investments?
- Vaxcyte, Inc. (PCVX) reported equity method investments of $1B in Q1 2026.
- How has Vaxcyte, Inc.'s equity method investments changed year-over-year?
- Vaxcyte, Inc.'s equity method investments decreased by 21.5% year-over-year, from $1.28B to $1B.
- What is the long-term trend for Vaxcyte, Inc.'s equity method investments?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s equity method investments has grown at a 138.8% compound annual growth rate (CAGR), from $27.12M to $881.66M.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.